Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli (NCT07482553) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli
Egypt60 participantsStarted 2026-05-01
Plain-language summary
1. Isolation of uropathogenic Escherichia coli (UPEC) and determination of their Antimicrobial sensitivity Patterns.
2. Evaluation of biofilm-forming capacity of UPEC isolates.
3. Assessment of the antibiofilm efficacy of chitosan nanoparticles alone and in combination with ciprofloxacin against UPEC isolates.
4. Examination of the effectiveness of chitosan nanoparticle coating in preventing biofilm formation by UPEC on urinary catheter surfaces.
5. Evaluation of the impact of chitosan nanoparticles on the expression levels of biofilm associated genes in UPEC.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. Patients (inpatients or outpatients) clinically diagnosed with urinary tract infection (UTI).
2\. Presence of significant bacteriuria in urine culture (≥10⁵ colony-forming units per milliliter (CFU/mL) for midstream urine, or as clinically indicated).
3\. Isolation of Escherichia coli as the sole or predominant pathogen from urine culture.
4\. Patients of any age and both sexes. 5. Patients who have not received antibiotic therapy within the previous 48-72 hours.
Exclusion Criteria:
* 1\. Patients who received systemic antibiotic therapy within the previous 48-72 hours prior to urine sample collection.
2\. Urine cultures showing insignificant bacteriuria (\<10⁵ CFU/mL for midstream urine, unless clinically justified).
3\. Polymicrobial growth in urine culture (mixed bacterial growth suggestive of contamination).
4\. Isolation of organisms other than Escherichia coli. 5. Improperly collected, leaking, or contaminated urine samples. 6. Patients unwilling to provide informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percentage of biofilm inhibition of UPEC isolates by chitosan nanoparticles alone and in combination with ciprofloxacin
Timeframe: 24 hours after treatment of bacterial cultures in vitro.